BRIEF-Spruce Biosciences On March 16, Entered Termination Agreement With Kaken Pharmaceutical - SEC Filing

Spruce Biosciences, Inc. -3.61% Post

Spruce Biosciences, Inc.

SPRB

63.63

63.63

-3.61%

0.00% Post

March 20 (Reuters) - SEC Filing:

  • SPRUCE BIOSCIENCES INC - ON MARCH 16, ENTERED TERMINATION AGREEMENT WITH KAKEN PHARMACEUTICAL - SEC FILING

  • SPRUCE BIOSCIENCES INC - COLLABORATION AGREEMENT WITH KAKEN PHARMACEUTICAL TO TERMINATE EFFECTIVE MARCH 31, 2026 - SEC FILING

  • SPRUCE BIOSCIENCES INC - ALL LICENSES & RIGHTS GRANTED BY CO TO KAKEN TO BE TERMINATDE; NO UNEARNED MILESTONE PAYMENTS OR ROYALTIES

Source text: [ID:n0001193125-26-117888]

Further company coverage: SPRB.O


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.